Swiss-based drug manufacturing firm Novartis AG is developing a drug tablet with an embedded microchip to promote greater compliance with drug regimens, Reuters News Service reports.

The chip is activated by stomach acid and sends a message to a small patch worn on the skin, which then transmits data via a smart phone or other Internet connection to a physician. In essence, the chip confirms to the physician that the patient took the medication at the right time and in the right dose.

The drug firm initially will focus on improving adherence rates with organ transplant patients, and expects to seek regulatory approval within 18 months. For the full Reuters story, click here.

--Joseph Goedert


Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access